ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Quercetin inhibits microglial pyroptosis following intracerebral hemorrhage via the TLR2/MyD88/NF-κB signaling pathway.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracerebral hemorrhage (ICH) is a severe stroke subtype with high mortality and limited therapies. Pyroptosis, a pro-inflammatory programmed cell death process, contributes critically to secondary brain injury (SBI) following ICH. This study aimed to identify pyroptosis-targeting therapeutic compounds and assess their protective effects in ICH. Pyroptosis-related characteristic differentially expressed ICH-related genes (DEICHRGs) were identified using bioinformatics and network pharmacology, leading to the screening of hub genes. Quercetin (Qu) was predicted as a key active component. Molecular docking was conducted between Qu and hub genes, and Toll-like receptor 2 (TLR2) was selected as a central regulatory target. In vivo and in vitro experiments were performed to assess the effects of Qu on neurological outcomes, microglial activation/polarization, and pyroptosis signaling. Qu ameliorated neurological deficits, reduced neuronal loss in perihematomal regions, and modulated microglial activation by suppressing pro-inflammatory phenotype and promoting anti-inflammatory polarization, and downregulated pyroptosis-associated proteins, including NOD-like receptor pyrin domain-containing protein 3 (NLRP3), cleaved Caspase-1 (CASP1), interleukin-1β (IL-1β), interleukin-18 (IL-18), and cleaved N-terminal Gasdermin D (GSDMD-N). In an oxyhemoglobin-induced BV2 cell model, Qu suppressed the TLR2/myeloid differentiation primary response 88 (Myd88)/nuclear factor-kappaB (NF-κB) pathway, thereby inhibiting NLRP3 inflammasome activation and pyroptosis. This inhibitory effect was reversed by a TLR2/1 agonist, confirming pathway specificity. Qu curbs microglial pyroptosis after ICH and exerts neuroprotective effects through the TLR2/MyD88/NF-κB signaling pathway.
Indexed as
Identifiers
41549176What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.